Roivant (ROIV) Director Oren Ilan Receives RSU and Option Awards

What Happened Oren Ilan, a director of Roivant Sciences Ltd. (ROIV), received two equity awards on September 16, 2026: 5,054 restricted stock units (RSUs) and a derivative grant of stock options covering 10,531 shares. Both grants were reported as awards (transaction code A) at $0.00 (no cash paid) and thus have no immediate purchase value.

Key Details

• Transaction date: 2026-09-16; Form 4 filed: 2026-09-18 (filed within the typical 2-business-day reporting window).
• RSUs: 5,054 shares granted; scheduled to vest 100% on September 16, 2027, subject to continued service as a director (see F1).
• Options: 10,531-share stock option award (derivative); scheduled to vest and become exercisable 100% on September 16, 2027, subject to continued service (see F2).
• Reported acquisition prices: $0.00 for both awards (standard for grants).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 describes the RSU annual award under the 2021 Equity Incentive Plan & Non-Employee Director Compensation Policy; F2 describes the annual stock option award under the same plans.

Context These are routine compensation awards to a non-employee director rather than open-market purchases or sales. They do not represent exercised options or immediate cash proceeds; vesting and exercisability are tied to continued service through September 16, 2027. Awards like this are common for directors and do not by themselves signal buying or selling intent in the open market.